AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009

LONDON, January 28 - Pharmaceutical group AstraZeneca announced it's Q4 and full-year results
today with CEO David Brennan saying in a video interview on
www.cantos.com that cost control and restructuring had helped deliver
a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23%
rise in core operating profit and, significantly, a 12% dividend increase. He
discusses the rationale behind the "significant" R&D changes that the company
is implementing as well as progress on the ongoing restructuring programme
and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term
future looks strong.

"We're entering a period of time where we are launching new products and
we're excited about them, but it's going to take a few years for those
products to get up to the revenue contribution that we need that will balance
some of the patent expirations."

The interview and transcript are available now on
www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email amanda.alexander@cantos.com or phone
+44-207-936-1352.

If you would like to contact us, please email amanda.alexander at cantos.com or phone
+44-207-936-1352.